mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...

The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...

Cordycepin, derived from fungi, shows promise in cancer therapy by inhibiting growth factor signaling pathways critical for ...

Using breast cancer patient-derived organoids and tumor ... Key changes include reduced activity of mTOR, a metabolic regulator, and structural shifts in E-cadherin, a molecule involved in cell ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Our research group is interested in understanding, at the structural and mechanistic levels, the maintenance of genomic integrity and the control of cell growth, both of which figure prominently in ...

Periodically abstaining from food helps intestinal stem cells regenerate and heal from injuries—but also increases cancer ...

Using breast cancer patient-derived organoids and tumor ... Key changes include reduced activity of mTOR, a metabolic regulator, and structural shifts in E-cadherin, a molecule involved in cell ...

Celcuity (CELC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oliver McCammon ...